logo
Plus   Neg
Share
Email

Amgen, Adaptive Partner To Find Neutralizing Antibodies For COVID-19

Amgen (AMGN) and Adaptive Biotechnologies (ADPT) announced they will collaborate to discover and develop fully human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19. The companies will begin work immediately and finalize financial terms in the coming weeks.

Adaptive Biotechnologies will extend its high throughput platform to screen the genetic diversity of the B cell receptors from individuals that have recovered from COVID-19. This enables the identification of antibodies from survivors of COVID-19 to select those that neutralize SARS-CoV-2.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Search giant Google, Inc. announced Wednesday that it signed an agreement to invest $4.5 billion or 33,737 crore Indian rupees in India's Jio Platforms Ltd, taking a 7.73 percent stake in the company, pending regulatory review in India. This investment by Google values Jio Platforms at an equity value... U.S. Bancorp (USB) reported second quarter earnings per share of $0.41, compared to $1.09, a year ago. On average, 22 analysts polled by Thomson Reuters expected the company to report profit per share of $0.22, for the quarter. Analysts' estimates typically exclude special items. Net income attributable... Flagstone Foods LLC is recalling certain Wegmans Pecan Blend Trail Mix citing the possible presence of undeclared almonds and walnuts, the U.S. Food and Drug Administration announced. The Robersonville, North Carolina-based company initiated the recall following a notification from a customer that the product contained almonds and walnuts that are not listed in the ingredient statement on the pack
Follow RTT